
Bio-Rad Laboratories (BIO) Stock Forecast & Price Target
Bio-Rad Laboratories (BIO) Analyst Ratings
Bulls say
Bio-Rad Laboratories is poised for growth in the coming years due to its diverse product portfolio and strong market positioning in its clinical diagnostics and life sciences divisions. The company's exposure to the conflict in the Middle East may have a short-term impact on its sales, but overall, the sales growth is expected to recover in 2027 after lapping headwinds related to process chromatography. Additionally, the recent restructuring efforts and new management team are expected to improve margins and drive further growth. The termination of the Sartorius Trust in 2028 will also increase the optionality and value of Bio-Rad's ownership stake in the company. While there are potential risks, such as a delay in end market recovery and competition in the ddPCR market, the company's strong product portfolio and focus on sustainability make it a compelling investment opportunity.
Bears say
Bio-Rad Laboratories is facing several challenges that are unique to the company, including declines in process chromatography sales due to changes in the CDC's immunization recommendations. However, the company's management is taking proactive steps to improve efficiencies and reduce expenses, which could result in a mid-teens operating margin goal by 2028-2029. There is also potential for upside in the company's ownership stake in Sartorius, which may become more valuable after the controlling Trust terminates in mid-2028. However, there are still risks to consider, such as a prolonged recovery in the life science tools industry and potential share losses in ddPCR. These factors warrant a cautious approach to Bio-Rad's stock, which is why the analyst has a negative outlook and a target price of $390, a discount to the peer group.
This aggregate rating is based on analysts' research of Bio-Rad Laboratories and is not a guaranteed prediction by Public.com or investment advice.
Bio-Rad Laboratories (BIO) Analyst Forecast & Price Prediction
Start investing in Bio-Rad Laboratories (BIO)
Order type
Buy in
Order amount
Est. shares
0 shares